Compare Novartis AG (NVS) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Zscaler Inc — how do they compare? Novartis AG trades at $139.7 (market cap $262.28B), while Zscaler Inc trades at $166 (market cap $27.08B). The key difference: Novartis AG is far larger — about 9.7× Zscaler Inc's market cap, and Novartis AG pays a 3.45% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.
| NVS | ZS | |
|---|---|---|
Market Cap | $262.28B | $27.08B |
Sector | Health | Technology |
52-Week High | $168.62 | $336.27 |
52-Week Low | $121.80 | $118.05 |
Enterprise Value | $303.60B | $25.47B |
Dividend Yield | 3.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.
The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.
Zscaler (ZS) trades at $161.94, down 4.63% today, reflecting bearish technical signals despite strong quarterly earnings beats. Revenue growth remains robust at 25% year-over-year in Q4 2026, though net income margins are negative. The stock faces headwinds from slowing growth guidance for FY2027 and elevated valuation multiples, with a consensus price target of $204.88 suggesting 26% upside. Recent news highlights AI security product launches and conference presentations.
Outlook is mixed: analyst sentiment is overwhelmingly bullish (79% buy ratings), but execution risks and decelerating top-line growth cloud near-term performance. Investment opportunity hinges on AI-driven cybersecurity demand offsetting margin pressures, while risks include competitive threats and capital expenditure increases impacting cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
